At the time of writing, Rhythm Pharmaceuticals Inc [RYTM] stock is trading at $103.27, up 1.56%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RYTM shares have gain 5.80% over the last week, with a monthly amount glided 18.33%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] stock has seen the most recent analyst activity on July 10, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $97. Previously, Leerink Partners started tracking the stock with Outperform rating on July 07, 2025, and set its price target to $88. On April 07, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $63 on the stock. Jefferies initiated its recommendation with a Buy and recommended $80 as its price target on January 02, 2025. Oppenheimer started tracking with a Outperform rating for this stock on December 20, 2024, and assigned it a price target of $76. In a note dated October 21, 2024, Guggenheim initiated a Buy rating and provided a target price of $70 on this stock.
For the past year, the stock price of Rhythm Pharmaceuticals Inc fluctuated between $43.57 and $101.74. Currently, Wall Street analysts expect the stock to reach $92.8 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $103.27 at the most recent close of the market. An investor can expect a potential drop of -10.14% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
According to Rhythm Pharmaceuticals Inc [NASDAQ:RYTM], the company’s sales were 156.29M for trailing twelve months, which represents an 66.80% jump. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.14%, Pretax Profit Margin comes in at -1.17%, and Net Profit Margin reading is -1.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -1.55 and Total Capital is -0.73. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 101.56 points at the first support level, and at 99.86 for the second support level. However, for the 1st resistance point, the stock is sitting at 104.92, and for the 2nd resistance point, it is at 106.58.
Ratios To Look Out For
It is important to note that Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] has a current ratio of 2.79. As well, the Quick Ratio is 2.64, while the Cash Ratio is 1.05. Considering the valuation of this stock, the price to sales ratio is 43.89.
Transactions by insiders
Recent insider trading involved JOSEPH SHULMAN, Officer, that happened on Aug 21 ’25 when 4188.0 shares were purchased. Chief Financial Officer, Smith Hunter C completed a deal on Aug 12 ’25 to sell 24611.0 shares. Meanwhile, Chief Financial Officer Smith Hunter C sold 3477.0 shares on Aug 13 ’25.
